Effects of Gu's Jianpi Yiqi Rougan Decoction combined with Entecavir on the efficacy, intestinal flora and intestinal mucosal barrier function in patients with compensated hepatitis B liver cirrhosis
-
摘要: 目的 观察并分析顾氏健脾益气柔肝方联合恩替卡韦对代偿期乙肝肝硬化患者疗效及肠道菌群、肠黏膜屏障功能的影响。方法 将符合标准的60例代偿期乙肝肝硬化患者随机分为中药组和对照组,对照组30例给予口服恩替卡韦分散片;中药组30例在口服恩替卡韦分散片同时加服顾氏健脾益气柔肝方。观察2组治疗后临床疗效、肝功能、肝纤维化指标、HBV-DNA、肠道菌群以及肠黏膜屏障功能的变化。结果 中药组在改善患者临床疗效上优于对照组。其中2组患者经治疗后,其肝功能指标(ALT、AST、TBIL)、肝纤维化指标、HBV-DNA数值、血清ET、D-乳酸、DAO水平较治疗前均显著下降,但中药组下降更优于对照组;ALB指标较治疗前均升高,但中药组上升更优于对照组;2组患者肠内双歧杆菌、乳杆菌数量均较疗前增多,大肠杆菌数量均较疗前下降,但中药组均优于对照组。结论 在常规西药抗病毒治疗上加用顾氏健脾益气柔肝方口服可提升早期乙肝肝硬化患者疗效, 其或依据“肠-肝轴”理论通过调节肠道菌群及修复肠黏膜屏障而起到治疗作用。Abstract: Objective To observe and analyze the effects of Gu's Jianpi Yiqi Rougan Decoction combined with Entecavir on the efficacy, intestinal flora and intestinal mucosal barrier function in patients with compensated hepatitis B cirrhosis.Methods Randomly dividing 60 patients with compensated hepatitis B cirrhosis that meet the criteria into two groups, 30 cases of control group: Given oral Entecavir dispersible tablets; 30 cases in Traditional Chinese Medicine group: In addition to taking orally Entecavir dispersible tablets and taking Gu's Jianpi Yiqi Rougan Decoction at the same time. The changes in clinical efficacy, liver function, liver fibrosis indicators, HBV-DNA, intestinal flora, and intestinal mucosal barrier function were observed in the two groups after treatment.Results The Traditional Chinese Medicine group was better than the control group in improving the clinical efficacy of patients. After treatment, the liver function indexes (ALT, AST, TBIL), liver fibrosis indexes, HBV-DNA value, serum ET, D-lactic acid, and DAO levels of the two groups were significantly decreased compared with those before treatment, but the Traditional Chinese Medicine group decreased. Better than the control group; ALB indexes were all higher than those before treatment, but the increase in the Traditional Chinese Medicine group was better than that in the control group; the number of bifidobacteria and lactobacilli in the intestines of both groups increased than before treatment, and the number of escherichia coli decreased, but the Traditional Chinese Medicine group was better than the control group.Conclusion Oral administration of Gu's Jianpi Yiqi Rougan Decoction in addition to conventional Western medicine antiviral therapy can improve the curative effect of patients with early hepatitis B cirrhosis, it may play a therapeutic role by regulating the intestinal flora and repairing the intestinal mucosal barrier according to the theory of "gut-liver axis".
-
表 1 2组患者一般资料的比较
X±S 组别 例数 性别/例 年龄/年 病程/年 Child-pugh评分/分 男 女 中药组 30 21 9 45.30±10.60 8.67±3.67 7.80±1.58 对照组 30 19 11 44.83±10.09 8.23±3.66 7.86±1.55 表 2 2组患者临床疗效比较
例 组别 治愈 显效 有效 无效 总有效率/% 中药组 15 7 4 4 86.671) 对照组 11 6 2 11 63.33 与对照组比较,1)P < 0.05。 表 3 2组患者肝功能、HBV-DNA指标比较
X±S 组别 时间 ALT/(U·L-1) AST/(U·L-1) TBIL/(μmol·L-1) ALB/(g·L-1) HBV-DNA/(×104U·mL-1) 中药组 治疗前 67.47±24.51 66.60±22.49 42.13±10.69 26.37±5.31 5.17±0.43 治疗后 45.40±6.271)2) 44.77±10.441)2) 18.67±3.741)2) 40.23±5.021)2) < 0.01a)1) 对照组 治疗前 66.17±24.47 69.50±22.84 41.83±10.19 25.80±5.18 5.20±0.38 治疗后 54.33±10.791) 56.00±13.841) 27.47±4.491) 34.77±3.771) < 0.01a)1) 注:a)治疗后HBV-DNA为 < 0.01×104U/mL。与同组治疗前比较,1)P < 0.05;与对照组治疗后比较,2)P < 0.05。 表 4 2组患者肝纤维化四项指标比较
ng/mL,X±S 组别 时间 PC-Ⅲ Ⅳ-C LN HA 中药组 治疗前 158.40±69.30 147.17±53.89 234.43±42.03 202.57±77.35 治疗后 108.23±35.161)2) 96.07±21.551)2) 184.17±15.521)2) 101.07±50.911)2) 对照组 治疗前 165.43±67.15 153.60±48.86 231.57±42.74 199.13±76.16 治疗后 127.27±34.831) 113.37±26.661) 204.87±23.131) 153.40±40.801) 与同组治疗前比较,1)P < 0.05;与对照组治疗后比较,2)P < 0.05。 表 5 2组患者治疗前后血清ET、D-乳酸和DAO水平比较
X±S 组别 时间 血清ET/(EU·mL-1) 血D-乳酸/(mmol·L-1) DAO/(U·L-1) 中药组 治疗前 0.39±0.09 5.45±0.69 7.86±0.89 治疗后 0.22±0.061)2) 3.94±0.471)2) 5.38±1.001)2) 对照组 治疗前 0.40±0.11 5.47±0.74 7.85±0.91 治疗后 0.28±0.091) 4.51±0.531) 6.46±0.831) 与同组治疗前比较,1)P < 0.05;与对照组治疗后比较,2)P < 0.05。 表 6 2组患者治疗前后菌群数量比较
CFU/g,X±S 组别 时间 双歧杆菌 乳杆菌 大肠杆菌 中药组 治疗前 7.27±0.68 5.91±0.70 9.84±0.58 治疗后 9.18±0.711)2) 8.04±0.761)2) 7.71±0.591)2) 对照组 治疗前 7.21±0.68 5.84±0.66 9.88±0.58 治疗后 8.05±0.721) 6.84±0.691) 8.88±0.551) 与同组治疗前比较,1)P < 0.05;与对照组治疗后比较,2)P < 0.05。 -
[1] Romanelli RG, Stasi C. Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis[J]. Curr Drug Targets, 2016, 17(15): 1804-1817. doi: 10.2174/1389450117666160613101413
[2] 王贵强, 段钟平, 王福生等. 慢性乙型肝炎防治指南(2019年版)[J]. 实用肝脏病杂志, 2020, 23(1): 9-32. https://www.cnki.com.cn/Article/CJFDTOTAL-GBSY202001046.htm
[3] 张记, 吴玉章. 慢性乙型肝炎治疗性疫苗研究进展[J]. 中华肝脏病杂志, 2021, 29(7): 631-635. doi: 10.3760/cma.j.cn501113-20210710-00332
[4] 时克, 张群, 黄云义, 等. 抗肝纤维化治疗对乙型肝炎肝硬化患者发生肝癌的影响[J]. 中华肝脏病杂志, 2021, 29(7): 685-689. doi: 10.3760/cma.j.cn501113-20200227-00072
[5] 何志钧, 宋怀宇. 肠道菌群与肝硬化关系的研究进展[J]. 医学综述, 2017, 23(20): 3984-3988. doi: 10.3969/j.issn.1006-2084.2017.20.007
[6] 中国中西医结合学会消化系统疾病专业委员会. 肝硬化中西医结合诊疗共识[J]. 中国中西医结合消化杂志, 2011, 19(4): 277-279. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXPW201104035.htm
[7] 中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社, 2002.
[8] 段桂姣, 王振常, 蒋锐沅, 等. 柔肝化纤颗粒对代偿期乙肝肝硬化肝肾阴虚型患者外周血NLRP3炎症小体及其产物表达的影响[J]. 南京中医药大学学报, 2021, 37(1): 25-30. https://www.cnki.com.cn/Article/CJFDTOTAL-NJZY202101008.htm
[9] 郭世奎, 包维民, 龚昆梅, 等. SYBR GreenⅠ实时荧光定量PCR法分析结直肠癌患者肠道菌群变化[J]. 中国普外基础与临床杂志, 2010, 17(5): 463-468. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL201005021.htm
[10] Zhang YR, Wang H, Zhang YD, et al. Highly sensitive nucleic acid detection and transaminase level in treatment decisions for Chinese patients with cirrhosis caused by hepatitis[J]. J Int Med Res, 2020, 48(10): 300060520959217.
[11] Brandl K, Kumar V, Eckmann L. Gut-liver axis at the frontier of host-microbial interactions[J]. Am J Physiol Gastrointest Liver Physiol, 2017, 312(5): G413-G419. doi: 10.1152/ajpgi.00361.2016
[12] 张翼, 黄茂辉, 陈丽君, 等. 肠黏膜通透性改变与肝硬化患者分级及预后的关系研究[J]. 中国当代医药, 2021, 28(27): 51-53. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD202127013.htm
[13] 刘礼剑, 李建锋, 陈广文, 等. "肠-肝轴"与肝硬化相关性研究进展[J]. 中国中西医结合消化杂志, 2021, 29(3): 222-226. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXPW202103014.htm
[14] 卢峪霞, 杨长青. 肠道微生态与慢性肝病研究进展[J]. 肝脏, 2019, 24(1): 92-95. https://www.cnki.com.cn/Article/CJFDTOTAL-ZUAN201901031.htm
[15] 顾林, 燕善军, 王启之, 等. 肝硬化患者肠黏膜屏障功能的变化[J]. 中华全科医学, 2014, 12(11): 1733-1735. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201411010.htm
[16] 张健荣, 顾尔莉, 王忠成. 扶正化瘀胶囊对乙肝肝硬化患者肝纤维化、肠黏膜屏障功能及免疫功能的影响[J]. 药学服务与研究, 2021, 21(3): 189-192, 199. https://www.cnki.com.cn/Article/CJFDTOTAL-YXFY202103008.htm
[17] 刘晋仙, 林永强, 汪冰, 等. 中药促进益生菌生长的研究进展[J]. 药学研究, 2015, 34(9): 537-538. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYG201509015.htm
[18] 陈建永, 施琳琳, 徐虹, 等. 正肝汤对肝硬化大鼠内毒素血症以及肠道细菌移位的影响[J]. 中华中医药学刊, 2016, 34(8): 2003-2006. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS201608061.htm
[19] 张铌雪, 姚魁武, 段锦龙. 活血化瘀法对肠道菌群结构及肠屏障功能影响的研究[J]. 中国微生态学杂志, 2018, 30(12): 1479-1482. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWS201812026.htm